Norway's Aker BioMarine has secured a new Lysoveta contract worth $4 million in first-year revenues.
Biotechnology innovator Aker BioMarine, a Norwegian company specializing in Antarctic krill harvesting and functional ingredient development, has finalized a new commercial contract for its Lysoveta delivery platform. The agreement is projected to generate $4 million in revenue during its first year, marking a significant commercial expansion for the company's specialized lipid portfolio.
The contract win arrives as the company initiates a broader corporate realignment. Aker BioMarine has retained investment banking firms Jefferies and Houlihan Lokey to evaluate strategic alternatives for its entire Human Health Ingredients business segment, with the explicit goal of executing a transaction within the year. This dual track of securing high-value contracts while exploring a segment divestment highlights an aggressive effort to maximize corporate valuation.
This development carries immediate implications for the global nutraceutical, pharmaceutical, and functional ingredient industries. Lysoveta, which focuses on targeted phospholipid delivery for brain and eye health, represents a highly specialized niche within the bio-ingredient supply chain. A prospective ownership transition of this division could alter market access, technology licensing, and sourcing dynamics for global life science enterprises and consumer health brands.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.